Explore Our Publications
At Magnolia Innovation, we are constantly striving to contribute meaningful data and analysis to the larger healthcare conversation.
Below are some of the independent and collaborative publications we have worked on recently.
Magnolia’s Perspective From ASCO 2024
Catalyst for Change: How Precision Medicine
Is Shifting Mindsets in Healthcare & Pharma
Precision medicine, a cornerstone of modern oncology, took center stage at ASCO 2024. This whitepaper digs into our key takeaways from ASCO and reflects on the implications for pharma and considerations for future market research based on the ever-evolving cancer diagnostics and treatment landscapes.
Magnolia’s Perspective From ASCO 2024
Catalyst for Change: How Precision Medicine
Is Shifting Mindsets in Healthcare & Pharma
Precision medicine, a cornerstone of modern oncology, took center stage at ASCO 2024. This whitepaper digs into our key takeaways from ASCO and reflects on the implications for pharma and considerations for future market research based on the ever-evolving cancer diagnostics and treatment landscapes.
Optimizing Clinical Trial Recruitment for Diversity and Inclusion
The Magnolia team was able to identify clinical trial recruitment strategies for Black and Hispanic patients through the pairing of our in-house claims database with custom primary market research.
Optimizing Clinical Trial Recruitment for Diversity and Inclusion
Recent findings suggest that Black and Hispanic patients were underdiagnosed and suboptimally treated for this condition and may experience a higher prevalence of this rare condition than previously reported.
Patient- and Caregiver-Reported Quality of Life and Burden of Disease in Wiskott-Aldrich Syndrome: Findings from a Multinational Survey
This multinational study aims to quantify both the caregiver and patient-related burdens of WAS and add to the existing literature by examining various domains of health-related QoL including symptom burden, transplant burden, time investment, social and emotional well-being, and professional status
Patient- and Caregiver-Reported Quality of Life and Burden of Disease in Wiskott-Aldrich Syndrome: Findings from a Multinational Survey
This multinational study aims to quantify both the caregiver and patient-related burdens of WAS and add to the existing literature by examining various domains of health-related QoL including symptom burden, transplant burden, time investment, social and emotional well-being, and professional status
The Broadsword and the Scalpel: Perspectives on Market Research in the Age of ChatGPT
What role can ChatGPT and its competitors play in market research?
BMT InfoNet Partners With Market Research Firm Magnolia Innovation to Better Understand Their Community’s Needs
Magnolia Innovation volunteers its market research expertise to uncover user experience issues to support BMT InfoNet website
BMT InfoNet Partners With Market Research Firm Magnolia Innovation to Better Understand Their Community’s Needs
Magnolia Innovation volunteers its market research expertise to uncover user experience issues to support BMT InfoNet website
Academic Execs Share How Pharma Should Engage With Oncology Customers
Academic Institution Executives Weigh In on the Importance of Knowing the Business Side of Oncology and the Impact of the Cross-Functional Teams That Exist within Pharma
Academic Execs Share How Pharma Should Engage With Oncology Customers
Academic Institution Executives Weigh In on the Importance of Knowing the Business Side of Oncology and the Impact of the Cross-Functional Teams That Exist within Pharma
Understanding the Impact of Long-chain Fatty Acid Oxidation Disorders for Patients and Caregivers
The Substantial Impact on Quality of Life for Individuals with LC-FAOD and Their Caregivers
Understanding the Impact of Long-chain Fatty Acid Oxidation Disorders for Patients and Caregivers
The Substantial Impact on Quality of Life for Individuals with LC-FAOD and Their Caregivers
Understanding Caregiver Descriptions of Initial Signs and Symptoms to Improve Diagnosis to Metachromatic Leukodystrophy
How Recognizing early signs can lead to earlier diagnosis and intervention in MLD patients
Understanding Caregiver Descriptions of Initial Signs and Symptoms to Improve Diagnosis to Metachromatic Leukodystrophy
How Recognizing early signs can lead to earlier diagnosis and intervention in MLD patients
An International Study of Caregiver – Reported Burden and Quality of Life in Metachromatic Leukodystrophy
How MLD Caregivers Lives are Negatively Affected By the Burden of care
An International Study of Caregiver – Reported Burden and Quality of Life in Metachromatic Leukodystrophy
How MLD Caregivers Lives are Negatively Affected By the Burden of care
C-Suite Insights: Are Oncology Pharma Teams Meeting Expectations?
A Customer-Driven Discussion About How Elevating Acumen In The Business of Oncology Can Strengthen Customer Impact
C-Suite Insights: Are Oncology Pharma Teams Meeting Expectations?
A Customer-Driven Discussion About How Elevating Acumen In The Business of Oncology Can Strengthen Customer Impact
Stress, Inflammation, and Suboptimal Treatment Outcomes
psychoneuroimmunology deepens our understanding of the mind-body connection and biological pathways through which mental and physical health interact.
Stress, Inflammation, and Suboptimal Treatment Outcomes
psychoneuroimmunology deepens our understanding of the mind-body connection and biological pathways through which mental and physical health interact.
Researching, Recognizing, and Reaching the Rare
Our team of market researchers, data scientists and consultants built a patient finding strategy tailored to our client’s needs
Researching, Recognizing, and Reaching the Rare
Our team of market researchers, data scientists and consultants built a patient finding strategy tailored to our client’s needs
Many Vendors or One Partner?
Read how a small biopharma company relied on a single vendor to launch a market-leading drug.
Many Vendors Or One Partner?
Read how a small biopharma company relied on a single vendor to launch a market-leading drug.
COVID-19: Impact on the Rare Disease Community
Learn the ways pharma can empower rare disease patients during the uncertainty of the COVID-19 Pandemic
COVID-19: Impact on the Rare Disease Community
Learn the ways pharma can empower rare disease patients during the uncertainty of the COVID-19 Pandemic
Oncologist Segmentation
Learn how to tailor personal and non-personal promotion based on attitudinal differences among oncologists
Oncologist Segmentation
Learn how to tailor personal and non-personal promotion based on attitudinal differences among oncologists
Benchmarking the COVID-19 Pandemic
Explore key lessons from other historical events to inform effective ways to manage the COVID-19 pandemic
Benchmarking the COVID-19 Pandemic
Explore key lessons from other historical events to inform effective ways to manage the COVID-19 pandemic
The Hidden Burden
Optimize commercial efforts by understanding the common challenges in the rare disease landscape
The Hidden Burden
Optimize commercial efforts by understanding the common challenges in the rare disease landscape
Understanding the Burden of Primary Hyperoxaluria Type 1 (PH1)
Understand the Debilitating effects of ph1 to identify the opportunities for Easier diagnosis and effective therapies
Understanding the Burden of Primary Hyperoxaluria Type 1 (PH1)
Understanding the Debilitating effects of Ph1 to identify the Opportunities for Easier diagnosis and effective therapies